The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

Building on almost 20 years of work at the United States National Institutes of Health (NIH), the Rockville, Maryland, biotech’s new polyclonal Th1/Tc1 cell therapy has shown promise in ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...